Kinase inhibitors are increasingly being explored for diseases beyond cancer. While SGK1 has been a cancer target, SGK1 has also been implicated in osteoarthritis pathology, and the Sanofi team developed “compound 17a” to interrogate this. The starting point was identified from ligand-based virtual screening, focusing on the DFG-out [...]
< 1 minute read
Jan. 17, 2022
Compound 17a: a SGK1 Inhibitor for Osteoarthritis
“compound 17a”
SGK1 kinase inhibitor preclinical activity in osteoarthritis explant model from DFG-out virtual screening, SBDD and MPO Journal of Medicinal Chemistry Sanofi, Frankfurt am Main, DE